4Tolwani A J, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial,2009,22 : 141-145.
5Binici DN, Gunes N. Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome. Ren Fail, 2010,32:469-474.
6Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low- molecular-weight heparin : mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safely. Chest, 2001,119( I Suppl) :64S-94S.
7van de Wetering J, Westendorp RG, van der ltoeven JG, et al. Heparin use in continuous renal replacement procedures: the struggle between filler coagulation and patient hemorrhage. J Am Soc Nephrol, 1996,7:145-150.
8Davenport A, Will E J, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron, 1994,66:431-437.
9Marlin PY, Chevrolet JC, Suter P, et al. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis, 1994,24:806-812.
10van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: preversus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif, 2005, 23 : 175-180.
